{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"17","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.","dispersionType":"Full Range","groups":[{"description":"Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.","id":"OG000","title":"Romiplostim"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 42 days","title":"Number of Days Post HDT-AHCT Requiring Transfusions or Grade 4 CTCAE Thrombocytopenia","type":"PRIMARY","unitOfMeasure":"days"}